Activity and Safety of Avelumab in High-Grade Neuroendocrine Tumors and Poorly Differentiated Neuroendocrine Carcinomas Progressive after Chemotherapy (AveNEC Trial)
In patients with progressive high-grade NEN G3, AVE was well tolerated and provided disease control with significant clinical benefit in 15% of heavily pretreated patients.
Authors
- Christian Fottner (ORCID: https://orcid.org/0000-0002-0091-0755)
- Anja Rinke (ORCID: https://orcid.org/0000-0002-8156-2915)
- Patrick Michl (ORCID: https://orcid.org/0000-0002-0401-5600)
- Wilfried Roth (ORCID: https://orcid.org/0000-0002-4847-9693)
- Jana Topsch (ORCID: https://orcid.org/0009-0000-6418-875X)
- Leonidas Apostolidis (ORCID: https://orcid.org/0000-0002-6358-8206)
- Daniel‐Christoph Wagner (ORCID: https://orcid.org/0000-0001-7516-5860)
- Barbara Grün
- Esther Mettler (ORCID: https://orcid.org/0000-0001-9910-5870)
- Sebastian Krug (ORCID: https://orcid.org/0000-0003-1672-7995)
- Christian Ruckes (ORCID: https://orcid.org/0000-0003-4823-0430)
- Peter R. Galle (ORCID: https://orcid.org/0000-0001-8294-0992)
- Thomas M. Gress (ORCID: https://orcid.org/0000-0002-9333-5461)
- Matthias M. Weber (ORCID: https://orcid.org/0000-0002-6939-2255)
Institutions
- Philipps University of Marburg (DE)
- University of Applied Sciences Mainz (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- Universitätsklinikum Gießen und Marburg (DE)
- University Hospital Heidelberg (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie (DE)
- National Center for Tumor Diseases (DE)
- University Hospital in Halle (DE)
- Martin Luther University Halle-Wittenberg (DE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2461
- Citations
- 8
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.26